Monoclonal Antibodies Against MMP9, Menke's Disease, and Wilson's Disease
A researcher at the University of California, Davis has developed the following monoclonal antibodies (mAbs), which are being made available for bailment as tangible research property:
A more detailed description of each clone can be found by searching the Neuromab Catalog (see www.neuromab.org).
These mAbs can be used to recognize their respective endogenous target proteins in tissue as well as the recombinant proteins for MMP9 matrix metalloproteinase 9, Menke's disease, and Wilson's disease.
L60/4 and L62/29 are the first anti-Menke's disease protein/Cu2+ transporting ATPase protein mAb and anti-Wilson's disease protein/Cu2+ transporting ATPase ß protein mAb, respectively.
monoclonal antibodies, mAbs, L60/4, L62/29, L51/57, L51/73, L51/80, L51/82, Wilson's disease, Menke's disease, MMP-9, MMP9, matrix metalloproteinase, MMP9 matrix metalloproteinase, L63/22, GPR49